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counted at 6%/yr, were obtained from HRG codes E18–19. Ben-
eﬁts were discounted at 1.5%. Extensive multivariate sensitivity
analyses were done. RESULTS: In these patients with mean age
of 64yrs, 91% in class III, 23% dead at two yrs, CRT reduced
hospitalization for heart failure by 42%, leading to total costs
of £3500 per patient vs. £3000 with OPT. Based on 100 repli-
cations, mean improvement of 0.16 QALY (SD 0.009) is
achieved with CRT at mean net cost of £526 (SD £167) per
patient, a mean cost-effectiveness ratio of £3379/QALY. Exten-
sive sensitivity analyses revealed the greatest cost/QALY vari-
ability when the length of stay for heart failure was varied ± 25%
(£562–£6354). CONCLUSION: Despite the cost of implanta-
tion, cardiac resynchronization therapy decreases hospitaliza-
tions and increases QOL sufﬁciently to be cost-effective in
treating advanced heart failure.
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OBJECTIVE: Combination therapy with isosorbide dinitrate
and hydralazine was recently shown to signiﬁcantly improve
clinical and survival outcomes in African Americans with con-
gestive heart failure (CHF). The objective of this analysis was to
measure the potential economic impact of this combination in
the US African American population with CHF. METHODS:
The population of African Americans with heart failure was esti-
mated from US Census Bureau and US NCHS 2002 NHANES
data. We then aggregated and compared drug and hospital costs
over a 10-month period (the duration of the trial) under a com-
bination therapy scenario vs. a usual-care scenario. Costs were
calculated in 2004 USD from the payer perspective. Cost of the
generic combination drug regimen (40mg isosorbide dinitrate
and 75mg hydralazine, three times daily) was calculated using
the AWP. The rates of ﬁrst hospitalizations for treated and
untreated patients were drawn from the trial (24.4% of patients
without drug combination and 16.4% with drug combination).
Hospital costs were estimated based on Medicare reimbursement
rates for DRG 127. RESULTS: The use of the drug combination
resulted in a cost savings of over $270 million dollars for the
entire population (n = 800,097), or $338 per person receiving
the drug combination. Cost savings with the drug combination
were realized over a wide range of clinical and cost parameters
and assumptions. CONCLUSION: Usage of the isosorbide dini-
trate and hydralazine combination in African Americans with
heart failure can be expected to generate cost savings in addition
to the signiﬁcant clinical beneﬁts of the drug combination.
Further studies of the drug combination over longer time hori-
zons, brand pricing (including pricing for a yet-to-be-approved
combination pill), and consideration of other costs such as treat-
ment of adverse events and physician fees will give a more 
complete picture of the beneﬁts of the drug combination in this
population.
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OBJECTIVE: To evaluate the incremental differences of concur-
rent and persistent use of angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, loop diuretics, and digoxin on the risk
of hospitalization and total costs with heart failure patients
enrolled in a managed care organization. METHODS: Retro-
spective database analysis of outpatients diagnosed with heart
failure within a managed care organization covering 350,000
lives from January 1, 1997 to December 31, 1999. Linear and
logistic regression models were used to examine the association
between treatment regimens and all-cause hospitalizations or
total direct medical costs after controlling for patient demo-
graphics, comorbidities, and other risk factors. RESULTS: Of the
1903 patients meeting inclusion and exclusion criteria, 33.2% 
(n = 615) were observed not to have received any ACE inhibitor,
beta-blocker, loop diuretic, digoxin, or angiotensin-receptor
blockers (ARB). Subsequent multivariate analyses indicated that
the associated risk of one year, all-cause hospitalization was 2.5
times higher (p < 0.01) for patients taking none of these med-
ications relative to the overall sample, followed by a 43.6%
higher total health care costs (p < 0.01). Patients receiving three
or more of the speciﬁc medications analyzed were associated
with signiﬁcant decreases in risk of one year all-cause hospital-
ization of approximately 80% (p < 0.01) and decreases in total
costs of approximately 70% (p < 0.01) relative to those utiliz-
ing no therapy. CONCLUSION: This analysis appears to indi-
cate that a substantial portion of heart failure patients may be
receiving suboptimal pharmacotherapeutic care, resulting in a
higher associated risk of hospitalization and increase in total
health care costs. Conversely, patients that were adherent with
concurrent medication therapies were associated with decreases
in both hospitalizations and total costs. The implications of this
research suggest that quality improvement initiatives seek to
identify and manage those not being treated or adherent to estab-
lished evidence-based care.
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Caremark has developed an in-home program that monitors
weight and symptoms using a telemonitoring device. The device
includes a special scale and telephone. A registered nurse 
monitors for any changes in the participant and further assesses
their condition. The goal of this program is to encourage par-
ticipants to weigh daily to recognize early symptoms and to
follow their physician. OBJECTIVE: To evaluate the effective-
ness of the CarePatterns heart failure home monitoring program.
METHODS: Participants were selected based on severity, not on
dialysis, not in any other monitoring program, not going out of
town, and fewer than 320 pounds. The objectives were to get
participants to meet selected benchmarks after 60 days. These
included daily weight taking, action plan, and when to call their
physician, no changes in weight or symptoms in prior 28 days,
and fewer than three Non-Compliance alerts in 28 days.
RESULTS: In total, 100 participants enrolled, 51% male 49%
female, mean age of 73. Seventy-seven individuals started daily
weight taking. A total of 54, or 71%, of these participants met
the graduation requirement. The retention rate for the CarePat-
terns Heart Failure program was 98% for the enrolled group and
80% for the non-enrolled group p < 0.05, 45 participants had
an alert, resulting in 16 doctor visits, two emergency room visits
and two hospitalizations, 32 participants did not have an alert.
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Conversely, these participants had 3-doctor visits, one emergency
room visit and two hospitalizations. Ninety-eight percent of the
graduated participants reported being satisﬁed with the program.
CONCLUSIONS: Enrollment in the CarePatterns Heart Moni-
toring program successfully trains participants to monitor their
weight daily and develop an Action Plan. The monitoring
program also increases overall retention and participants report
strong satisfaction with the program. These factors all should
contribute to lower medical utilization and improved clinical
outcomes.
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Until the mid-1990s, Canadian consensus guidelines identiﬁed ß-
blocker therapy as being contraindicated for persons with heart
failure (HF). Based on placebo-controlled randomized trials and
economic evaluations that appeared subsequently, more recent
consensus statements reversed that recommendation and advo-
cated widespread use of ß-blockers for moderate to severe HF.
OBJECTIVES: Our goal was to estimate, among elderly persons
discharged after a ﬁrst HF hospitalization, the extent to which
ß-blocker use increased after the reversal in recommendations.
METHODS: We carried out a retrospective cohort study using
a linked administrative database of hospital separations and
medication claims. Included were all residents of British Colum-
bia, Canada (BC), aged 65 years and over, sent home after being
hospitalized with a principal discharge diagnosis of HF during
ﬁscal years 1990–2001. To eliminate prevalent hospitalizations,
we excluded subjects discharged with any diagnosis of HF
between 1990 and 1993. The proportion dispensed a ß-blocker
within 30 days of discharge was estimated for triennial periods
and was modeled using logistic regression. RESULTS: For all
subjects, the proportion dispensed a ß-blocker after their ﬁrst
hospitalization for HF increased from 2.2% in 1993–95 through
4.0% in 1996–98 to 7.4% in 1998–2001 (crude odds ratio =
3.6; 95% conﬁdence interval 3.3 to 3.9). CONCLUSIONS: In
this population-based study, we found that in the latter half of
the 1990s, there was a three-fold increase in the use of ß-blocker
therapy after an initial hospitalization for HF, consistent with
new guidelines. However, absolute rates of ß-blocker use
remained lower than 10% in BC, indicating that many patients
may yet be receiving the beneﬁt.
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OBJECTIVES: To examine patterns of use of drugs for the treat-
ment of chronic heart failure (CHF) and how these patterns
change over time. METHODS: We identiﬁed a national cohort
of patients with CHF in the Department of Veterans Affairs (VA)
beginning October 1, 1998 (FY99) and obtained their outpatient
pharmacy prescription ﬁll records for FY99 through FY02. We
tabulated the proportion of patients receiving ﬁlled prescriptions
for several categories of drugs across years. To adjust for sever-
ity of illness and distinguish birth cohort effects from real
changes in practice, patients were stratiﬁed based on number of
years in the cohort. We then compared patterns of use between
groups over time. RESULTS: The total number of patients
ranged from 222,288 in FY99 to 301,485 in FY02. The average
age(sd) ranged from 69.7(10.3) to 71.1(10.4). The most preva-
lent categories in FY99 were angiotensin-converting enzyme
(ACE) or angiotensin II inhibitors (65.6%), loop diuretics
(64.2%), digitalis glycosides (40.3%), calcium channel blockers
(CCB, 37.0%), beta blockers (37.1%) and statins (36.3%). By
FY02, digitalis and CCBs decreased to 34.0% and 32.4%, 
while beta blockers and statins increased to 54.0% and 51.8%,
respectively. ACE or angiotensin II inhibitor and loop diuretic
use remained relatively constant (69.3% and 62.3%, respec-
tively). Among newly diagnosed patients, 40.6% in FY99
received beta blockers; in FY02, 58.8% were started on beta
blockers. Of survivors from FY99, beta blocker use increased to
52.7% by FY02, indicating that 29.8% of surviving patients
were added to beta blockers and/or survived longer than patients
who were not started on that drug class. Similar patterns were
observed within other groups. CONCLUSIONS: Pharmacother-
apy patterns in the VA changed for patients with CHF from 1999
to 2002, as new evidence emerged from clinical trials. Future
work will link these changes in process of care to survival, 
utilization and cost.
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OBJECTIVE: Heart failure (HF) is a debilitating chronic condi-
tion characterized by steady deterioration that is punctuated
with acute episodes of decompensation requiring hospitalization.
It is among the most costly conditions, consuming between two
and 3% of health care budgets in western countries, 2/3 of which
is spent on hospitalizations. During the 1980s, increasing age-
speciﬁc hospitalization rates of HF were observed. However,
there is little Canadian information on trends in HF hospital-
izations during the 1990s, a period when efﬁcacious therapies
for HF, including angiotensin converting enzymes and ß-block-
ers, were being progressively incorporated into clinical practice.
METHODS: Using the hospital separations database, we
obtained abstracts of all residents of British Columbia, Canada
(BC), aged 40 years and over, having a principal discharge diag-
nosis of HF during ﬁscal years 1990–2001. To eliminate preva-
lent hospitalizations, we excluded subjects who were discharged
with any diagnosis of HF between 1990 and 1993. Age- and 
sex-speciﬁc, and directly age-standardized, rates of initial HF
hospitalization were estimated using population denominators.
Poisson regression was used to model changes over time.
RESULTS: For both women and men, age-standardized rates
decreased 37% from 1993 to 2001. Decreases of this magnitude
were observed over all ages. CONCLUSIONS: In this popula-
tion-based study, we found that declines in rates of initial 
hospitalization for HF occurred in BC at the same time that efﬁ-
cacious therapies were incorporated into practice. While this
ﬁnding is encouraging, alternative explanations such as concur-
rent hospital downsizing that restricted admission to more severe
cases, must be ruled out before concluding that persons with HF
were managed better.
